スライド2.PNG.png

アプリ案内

General information

Announcements(1)

Program

Sessions

Search presentations

Download PDF for print

Timetable

Wed. Dec 3, 2025

Thu. Dec 4, 2025

Fri. Dec 5, 2025

web_header_en.png

web_icon.png

Profile management

Announcements

Bookmark

Program Type

Use of the AI Simultaneous Interpretation System

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

Please enter the password printed on your name card.<br>Online registrants can download your name card from the account page once payment has been successfully processed.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Development of iPSC derived GD2 targeted chimeric antigen receptor T cell therapy for GD2 positive tumors

Chimeric Antigen Receptor (CAR) T-cell therapy is a groundbreaking technology that endows cells with new functionalities, bridging the fields of regenerative medicine and gene therapy to treat a variety of diseases. While regulatory authority-approved CAR-T therapies have shown dramatic effects, several challenges remain. This symposium will build upon the successes of CAR-T therapy, focusing on advancements in cell targeting techniques and the development of novel vectors. We will share and discuss the latest insights for clinical applications of next-generation technologies, aiming to accelerate the translation of molecular biology innovations into medical practice.

【E】Beyond CAR-T: Pioneering New Horizons in Designer Cell Technology

The 48th Annual Meeting of the Molecular Biology Society of Japan

Presentation Information

[2AS-10-06]Development of iPSC derived GD2 targeted chimeric antigen receptor T cell therapy for GD2 positive tumors

Password required to view

Comment